Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 89, Issue 4, Pages 363-368
Publisher
Wiley
Online
2013-11-25
DOI
10.1002/ajh.23640
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity
- (2013) Siddhartha Sen et al. EXPERIMENTAL HEMATOLOGY
- Iron Chelators for the Treatment of Cancer
- (2012) Y. Yu et al. CURRENT MEDICINAL CHEMISTRY
- Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors
- (2012) Vinod Pullarkat et al. LEUKEMIA RESEARCH
- Wnt Signaling, Stem Cells, and Cancer of the Gastrointestinal Tract
- (2012) A. Schepers et al. Cold Spring Harbor Perspectives in Biology
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
- (2011) Joseph Chao et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Wnt Inhibitor Screen Reveals Iron Dependence of -Catenin Signaling in Cancers
- (2011) S. Song et al. CANCER RESEARCH
- The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress
- (2011) Judith M. Myers et al. TOXICOLOGY LETTERS
- Ciclopirox
- (2010) Alessandro Subissi et al. DRUGS
- The antitumor activity of the fungicide ciclopirox
- (2010) Hongyu Zhou et al. INTERNATIONAL JOURNAL OF CANCER
- The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy
- (2010) S. J. Weir et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
- (2010) Celine Callens et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase
- (2009) Lijun Zhu et al. BIOCHEMICAL PHARMACOLOGY
- Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG
- (2009) François Gaboriau et al. BIOMETALS
- Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells
- (2009) Y. Eberhard et al. BLOOD
- Fluorescence properties and cellular distribution of the investigational anticancer drugTriapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(ii) complex
- (2009) Christian R. Kowol et al. DALTON TRANSACTIONS
- Targeting Wnt pathway in lymphoma and myeloma cells
- (2008) Matthias Schmidt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
- (2008) Olatoyosi M. Odenike et al. INVESTIGATIONAL NEW DRUGS
- A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders
- (2007) Judith E. Karp et al. LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search